利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.031 秒)

    System for endoscopic imaging and method for processing images
    2.
    发明授权
    System for endoscopic imaging and method for processing images 有权

    公开(公告)号：US11432705B2

    公开(公告)日：2022-09-06

    申请号：US16624593

    申请日：2018-06-22

    申请人： Helmholtz Zentrum Munchen Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (GMBH)

    发明人： Maximilian Koch ,  Vasilis Ntziachristos

    IPC分类号： A61B1/00 ,  A61B1/005 ,  A61B1/04 ,  A61B1/05 ,  G06T7/00

    摘要： The invention relates to a system for endoscopic imaging comprising a light source configured to generate light and an, in particular rigid, insertion portion configured to be inserted into an object and comprising a distal end, a proximal end and at least one light guiding path. The system further comprises a first imaging device mounted at the proximal end of the insertion portion and optically coupled to the light guiding path, the first imaging device comprising a plurality of first detecting elements exhibiting a first sensitivity to light. A flexible guiding portion comprising a distal end and a proximal end is provided to guide a second part of the light emanating from the medium from the distal end of the guiding portion to the proximal end of the guiding portion. A second imaging device provided at the proximal end of the flexible guiding portion comprises a plurality of second detecting elements exhibiting a second sensitivity to light, the second sensitivity of the second detecting elements being higher than the first sensitivity of the first detecting elements. A control unit is configured to derive at least one third image of the medium based on image data of the at least one first image of the medium and image data of the at least one second image of the medium. The invention further relates to a corresponding method for processing images.

    COMPOSITIONS FOR THE PREPARATION OF MATURE DENDRITIC CELLS
    8.
    发明申请
    COMPOSITIONS FOR THE PREPARATION OF MATURE DENDRITIC CELLS 审中-公开
    用于制备成熟细胞的组合物

    公开(公告)号：US20170037372A1

    公开(公告)日：2017-02-09

    申请号：US15333476

    申请日：2016-10-25

    申请人： Helmholtz Zentrum Munchen Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH)

    发明人： Dolores J. SCHENDEL ,  Anke ZOBYWALSKI ,  Iris BIGALKE

    IPC分类号： C12N5/0784 ,  A61K35/15

    摘要： The invention relates to a method for in vitro maturation of at least one immate dendritic cell, comprising stimulating said immature dendritic cell with TNFα, IL-1β, IFNγ, a TLR7/8 agonist and prostaglandin E2(PG). Furthermore, the invention elates to a composition comprising these factors as well as to mature dendritic cells produced by a method of the invention.

    摘要翻译： 本发明涉及一种用于体外成熟至少一种死亡树突状细胞的方法，包括用TNFα，IL-1β，IFNγ，TLR7 / 8激动剂和前列腺素E2（PG）刺激所述未成熟树突状细胞。 此外，本发明涉及包含这些因素的组合物以及通过本发明的方法产生的成熟树突状细胞。

    Biomarkers for type 2 diabetes
    9.
    发明授权
    Biomarkers for type 2 diabetes 有权
    2型糖尿病生物标志物

    公开(公告)号：US09546994B2

    公开(公告)日：2017-01-17

    申请号：US14421637

    申请日：2013-08-13

    申请人： Helmholtz Zentrum Munchen—Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH) ,  Deutsche Diabetes-Forschungsgesellschaft e.V.—Trager des Deutschen Diabetes-Zentrums Dusseldorf ,  Eberhard Karls Universitat Tubingen, Medizinische Fakultat

    发明人： Wolfgang Rathmann ,  Christian Herder ,  Thomas Illig ,  Jerzy Adamski ,  Rui Wang-Sattler ,  Zhongao Yu ,  H.-Erich Wichmann ,  Hans-Ulrich Haring ,  Michael Roden ,  Annette Peters ,  Christine Meisinger ,  Martin Hrabe De Angelis ,  Thomas Meitinger

    IPC分类号： G01N33/92 ,  G01N33/487 ,  G01N33/68 ,  G01N24/08 ,  G01N30/02 ,  G01N30/72 ,  G01N33/49

    CPC分类号： G01N33/487 ,  G01N24/08 ,  G01N30/02 ,  G01N30/7206 ,  G01N33/49 ,  G01N33/6893 ,  G01N33/92 ,  G01N2030/025 ,  G01N2030/027 ,  G01N2500/10 ,  G01N2800/042 ,  G01N2800/50

    摘要： The present invention relates to a method of identifying a predisposition for developing type 2 diabetes mellitus in a subject, said method comprising the step of assessing in a sample obtained from said subject the amount of one or more metabolite(s) selected from (a) a first group comprising the metabolites glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2, phosphatidylcholine acyl-alkyl C36:3 and isobaric metabolites having the same molecular mass as glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2 or phosphatidylcholine acyl-alkyl C36:3 but different chemical formula; and/or (b) a second group comprising the metabolite acetylcarnitine C2 and an isobaric metabolite having the same molecular weight as acetylcarnitine C2 but different chemical formula; wherein a decrease in the amount of a metabolite selected from said first group or an increase in the amount of a metabolite selected from said second group as compared to the amount of the corresponding metabolite(s) of a control is indicative of a predisposition to develop type 2 diabetes mellitus. Further, the invention relates to a method of identifying a compound capable of preventing type 2 diabetes mellitus and diseases associated therewith or serving as a lead compound for developing a compound capable of preventing type 2 diabetes mellitus and diseases associated therewith and a method of selecting a therapy to prevent type 2 diabetes mellitus. Also, the invention relates to a kit.

    摘要翻译： 本发明涉及鉴定受试者中2型糖尿病发病倾向的方法，所述方法包括以下步骤：在从所述受试者获得的样品中评估选自（a）的一种或多种代谢物的量， 第一组包括代谢物甘氨酸，溶血磷脂酰胆碱酰基C18：2，溶血磷脂酰胆碱酰基C17：0，溶血磷脂酰胆碱酰基C18：0，溶血磷脂酰胆碱酰基C18：1，磷脂酰胆碱酰基 - 烷基C34：2，磷脂酰胆碱酰基 - 烷基C36：2，磷脂酰胆碱酰基 - 烷基C36：3和具有与甘氨酸相同分子量的等压代谢物，溶血磷脂酰胆碱酰基C18：2，溶血磷脂酰胆碱酰基C17：0，溶血磷脂酰胆碱酰基C18：0，溶血磷脂酰胆碱酰基C18：1，磷脂酰胆碱酰基 - 烷基C34：2，磷脂酰胆碱酰基 - 烷基C36：2或磷脂酰胆碱酰基 - 烷基C36：3但化学式不同; 和/或（b）包含代谢物乙酰肉碱C2和具有与乙酰肉碱C2相同的分子量但不同化学式的等压代谢物的第二组; 其中与对照的相应代谢物的量相比，选自所述第一组的代谢物的量的减少或选自所述第二组的代谢物的量的增加表明发生倾向 2型糖尿病 此外，本发明涉及鉴定能够预防2型糖尿病和与其相关的疾病或作为用于开发能够预防2型糖尿病和相关疾病的化合物的铅化合物的化合物的方法，以及选择 治疗预防2型糖尿病。 此外，本发明涉及一种试剂盒。

    EPSTEIN-BARR-VIRUS VACCINE
    10.
    发明申请
    EPSTEIN-BARR-VIRUS VACCINE 审中-公开

    公开(公告)号：US20160296618A1

    公开(公告)日：2016-10-13

    申请号：US15077477

    申请日：2016-03-22

    申请人： HELMHOLTZ ZENTRUM MUNCHEN DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH)

    发明人： Romana Ruiss ,  Gilbert Reisbach ,  Wolfgang Hammerschmidt ,  Reinhard Zeidler

    IPC分类号： A61K39/245 ,  C07K14/005 ,  C12N7/00

    CPC分类号： A61K39/245 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/57 ,  A61K2039/575 ,  C07K14/005 ,  C07K2317/569 ,  C12N7/00 ,  C12N2710/16223 ,  C12N2710/16234 ,  C12N2710/16252 ,  C12N2710/16262 ,  C12N2710/16271

    摘要： The present invention relates to a vaccine comprising a particle, said particle comprising (i) at least one Epstein-Barr virus (EBV) structural polypeptide, (ii) at least one EBV lytic polypeptide, (iii) membrane lipids, said particle being devoid of EBV DNA, wherein (a) the B-cell transformation capacity of one or more EBV polypeptides required for B-cell transformation as comprised in said particle is disabled while their immunogenicity is maintained; and or (b) said particle is devoid of one or more EBV polypeptides required for B-cell transformation. Furthermore, the invention relates to a method for generating a particle, to a cell obtained in the method of the invention, a kit comprising the vaccine or the particle generated according in the method of the invention. Also, the invention relates to the use of the vaccine or the particle generated according to the method of the invention for generating CD8+ cells specific for an EBV antigen.

    摘要翻译： 本发明涉及包含颗粒的疫苗，所述颗粒包含（i）至少一种爱泼斯坦 - 巴尔病毒（EBV）结构多肽，（ii）至少一种EBV溶解多肽，（iii）膜脂质，所述颗粒无缺陷 的EBV DNA，其中（a）包含在所述颗粒中的B细胞转化所需的一种或多种EBV多肽的B细胞转化能力在其免疫原性保持时被禁用; 和（b）所述颗粒没有B细胞转化所需的一种或多种EBV多肽。 此外，本发明涉及一种生成颗粒的方法，本发明方法获得的细胞，包含根据本发明方法生成的疫苗或颗粒的试剂盒。 此外，本发明涉及根据本发明的方法产生的疫苗或颗粒用于产生对EBV抗原特异性的CD8 +细胞的用途。